- Conditions
- Solid Tumors
- Interventions
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 895
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
- Interventions
- Test for circulating tumor cells, DNA alterations
- Diagnostic Test
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- capecitabine, docetaxel
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 28
- States / cities
- Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 20 more
- Conditions
- Barrett's Esophagus, CIS, HGD
- Interventions
- HPPH
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Esophageal Cancer
- Interventions
- C11-Choline
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
- Interventions
- irinotecan hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma
- Interventions
- Specimen Collection
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Barrett's Esophagus With High Grade Dsyplasia, Early Esophageal Cancer
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Esophageal Adenocarcinoma
- Interventions
- FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
- Interventions
- Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU), Carboplatin
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Lung Cancer, Esophageal Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Esophageal Cancer
- Interventions
- conventional surgery, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, chemotherapy, Radiotherapy
- Procedure · Radiation · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 26 more
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
- Interventions
- Not listed
- Lead sponsor
- Travera Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IV Esophageal Cancer
- Interventions
- arsenic trioxide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer (GC), Colorectal Cancer Screening
- Interventions
- Not listed
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
- Interventions
- Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Docetaxel, Esophagectomy, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2036
- U.S. locations
- 96
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
- Interventions
- IMT-009, Fruquintinib
- Drug · Combination Product
- Lead sponsor
- Immunitas Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more
- Conditions
- Triple Negative Breast Cancer, Head & Neck Cancer, Esophageal Cancer
- Interventions
- PCA062
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Houston, Texas • San Antonio, Texas
- Conditions
- Barrett's Esophagus, Gastroesophageal Reflux Disease, Esophageal Adenocarcinoma
- Interventions
- Not listed
- Lead sponsor
- Midwest Biomedical Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2029
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Interventions
- JAB-3068
- Drug
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
- Conditions
- Gastric Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Biliary Cancer
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastroesophageal Reflux Disease, Esophageal Cancer, Barrett's Esophagus
- Interventions
- Decision Aid
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Esophageal Neoplasms
- Interventions
- CD40 Gene Transfer
- Genetic
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 2
- States / cities
- Ridgewood, New Jersey • New York, New York
- Conditions
- Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma, Endometrial Cancer, Uterine Cancer, Ovarian Cancer, Carcinosarcoma, Gastric Cancer
- Interventions
- DKN-01
- Drug
- Lead sponsor
- Leap Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 2 more